Cercare il medicinale per il nome

Totacillin-N injection e Disfunzione renale

Risultato del controllo d'interazione tra il farmaco Totacillin-N injection e la malattia Disfunzione renale su sicurezza in caso d'uso simultaneo.

Risultato di controllo:

Totacillin-N injection <> Disfunzione renale

Rilevanza: 23.07.2019 Recensore: P.M. Shkutko, dott., in

Durante il controllo d'interazione, secondo le fonti autorevoli Drugs.com, Rxlist.com, Webmd.com, Medscape.com sono trovate le controindicazioni o gli effetti collaterali che possono danneggiare oppure intensificare l’effetto negativo in caso d'uso del farmaco in presenza di questa malattia concomitante.

Consumatore:

Più antibiotici beta-lattamici sono eliminati per via renale come farmaco immodificato e, in alcuni casi, anche come metaboliti. Le concentrazioni sieriche di antibiotici beta-lattamici e dei loro metaboliti possono essere aumentati e l'emivita prolungata in pazienti con funzione renale compromessa. Neurotossico reazioni, tra cui encefalopatia, asterixis, mioclono, convulsioni e coma, sono stati segnalati in pazienti trattati per via parenterale con questi agenti. Dosaggio possono essere necessarie rettifiche e modifiche dovrebbero essere in base al grado di compromissione renale, nonché della gravità dell'infezione, in conformità con il singolo prodotto, la confezione e l'etichettatura. Test di funzionalità renale deve essere eseguita periodicamente, durante un prolungato e/o a terapia ad alte dosi, poiché la nefrotossicità e alterazioni della funzione renale, occasionalmente sono stati associati con l'uso di questi farmaci.

Fonte

"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome, Research Triangle Park, NC.
Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974): 36-52
Pazin GJ, Schwartz SN, Ho M, Lyon JA, Pasculle AW "Treatment of septicemic patients with cefoxitin: pharmacokinetics in renal insufficiency." Rev Infect Dis 1 (1979): 189-94
Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 Suppl 1 (1985): s145-50
Kampf D, Schurig R, Korsukewitz I, Bruckner O "Cefoxitin pharmacokinetics: relation to three different renal clearance studies in patients with variuos degrees of renal insufficiency." Antimicrob Agents Chemother 20 (1981): 741-6
Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR "Nephrotoxicity associated with cephalothin administration." Arch Intern Med 135 (1975): 797-801
Aronoff GR, Sloan RS, Brier ME, Luft FC "The effect of piperacillin dose on elimination kinetics in renal impairment." Eur J Clin Pharmacol 24 (1983): 543-7
Blum RA, Kohli RK, Harrison NJ, Schentag JJ "Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis." Antimicrob Agents Chemother 33 (1989): 1470-6
Grcevska L, Polenakovic M "Second attack of acute tubulointerstitionephritis induced by cefataxim and pregnancy." Nephron 72 (1996): 354-5
Meyers BR, Hirschman SZ "Pharmacokinetics of cefamandole in patients with renal failure." Antimicrob Agents Chemother 11 (1977): 248-50
Madhavan T, Yaremchuk K, Levin N, et al "Effects of renal failure and dialysis on cefazolin pharmacokinetics." Antimicrob Agents Chemother 8 (1975): 63-6
Brogard JM, Kopferschmitt J, Spach MO, et al "Cefamandole pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 19 (1979): 366-77
Smith BR, LeFrock JL, Thyrum PT, et al "Cefotetan pharmacokinetics in volunteers with various degrees of renal function." Antimicrob Agents Chemother 29 (1986): 887-93
Wade JC, Schimpff SC, Wiernik PH "Antibiotic combination - associated nephrotoxicity in granulocytopenic patients with cancer." Arch Intern Med 141 (1981): 1789-93
Pasternak DP, Stephens BG "Reversible nephrotoxicity associated with cephalothin therapy." Arch Intern Med 135 (1975): 599-602
Sherman RA, Eisinger RP, Weinstein MP, Samel J "Cefoxitin-induced pseudo acute renal failure." Clin Ther 4 (1981): 114-7
Fillastre JP, Leroy A, Humbert G, Godin M "Pharmacokinetics of cefotaxime in subjects with normal and impaired renal function." J Antimicrob Chemother 6 (1980): 103-11
Bechtel TP, Slaughter RL, Moore TD "Seizures associated with high cerebrospinal fluid concentrations of cefazolin." Am J Hosp Pharm 37 (1980): 271-3
"Product Information. Mefoxin (cefoxitin)." Merck & Co, Inc, West Point, PA.
Welage LS, Schultz RW, Schentag JJ "Pharmacokinetics of ceftazidime in patients with renal insufficiency." Antimicrob Agents Chemother 25 (1984): 201-4
Haskell RJ, Fujita NK, Stevenson JA, Border WA "Cefoxitin-induced interstitial nephritis." Arch Intern Med 141 (1981): 1557
Davies M, Morgan JR, Anand C "Administration of ticarcillin to patients with severe renal failure." Chemotherapy 20 (1974): 339-41
McCloskey RV, Terry EE, McCracken AW, Sweeney MJ, Forland MF "Effect of hemodialysis and renal failure on serum and urine concentrations of cephapirin sodium." Antimicrob Agents Chemother 1 (1972): 90-3
Lewis JA, Rindone JP "Acute interstitial nephritis associated with cephapirin." Drug Intell Clin Pharm 21 (1987): 380-1
Walstad RA, Nilsen OG, Berg KJ "Pharmacokinetics and clinical effects of cefuroxime in patients with severe renal insufficiency." Eur J Clin Pharmacol 24 (1983): 391-8
Wise R, Wright N, Wills PJ "Pharmacolgy of cefotaxime and its desacetyl metabolite in renal and hepatic disease." Antimicrob Agents Chemother 19 (1981): 526-31
"Product Information. Staphcillin (methicillin)." Apothecon Inc, Plainsboro, NJ.
Burton JR, Lichtenstein NS, Colvin RB, Hyslop NE, Jr "Acute renal failure during cephalothin therapy." JAMA 229 (1974): 679-82
Fillastre JP, Leroy A, Godin M, Oksenhendler G, Humbert G "Pharmacokinetics of cefoxitin sodium in normal subjects and in uraemic patients." J Antimicrob Chemother 4 (1978): 79-83
Ohkawa M, Nakashima T, Shoda R, et al "Pharmacokinetics of ceftazidime in patients with renal insufficiency and in those undergoing hemodialysis." Chemotherapy 31 (1985): 410-6
Fillastre JP, Leroy A, Baudoin C, et al "Pharmacokinetics of aztreonam in patients with chronic renal failure." Clin Pharmacokinet 10 (1985): 91-100
Rodjer S, Alestig K, Bergmark J, et al "Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects." J Antimicrob Chemother 20 (1987): 109-16
Dubb J, Actor P, Pitkin D, et al "Ceftizoxime kinetics and renal handling." Clin Pharmacol Ther 31 (1982): 516-21
Wright N, Wise R "The elimination of sulbactam alone and combined with ampicillin in patients with renal dysfunction." J Antimicrob Chemother 11 (1983): 583-7
Aronoff GR, Wolen RL, Obermeyer BD, Black HR "Pharmacokinetics and protein binding of cefamandole and its 1-methyl-1 H-tetrazole-5-thiol side chain in subjects with normal and impaired renal function." J Infect Dis 153 (1986): 1069-74
Smith H, Lerner PI, Weinstein L "Neurotoxicity and "massive" intravenous therapy with penicillin." Arch Intern Med 120 (1967): 47-53
Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970): 57-9
Pitkin D, Dubb J, Actor P, et al "Kinetics and renal handling of cefonicid." Clin Pharmacol Ther 30 (1981): 587-93
Klion AD, Kallsen J, Cowl CT, Nauseef WM "Ceftazidime-related nonconvulsive status epilepticus." Arch Intern Med 154 (1994): 586-9
"Product Information. Mandol (cefamandole)." Lilly, Eli and Company, Indianapolis, IN.
Frimodt-Moller N, Maigaard S, Toothaker RD, et al "Mezlocillin pharmacokinetics after single intravenous doses to patients with various degrees of renal function." Antimicrob Agents Chemother 17 (1980): 599-607
Fillastre J-P, Fourtillan J-B, Leroy A, et al "Pharmacokinetics of cefonicid in uraemic patients." J Antimicrob Chemother 18 (1986): 203-11
"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome, Research Triangle Park, NC.
"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb, Princeton, NJ.
Martinez-Rodriguez JE, Barriga FJ, Santamaria J, et al. "Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure." Am J Med 111 (2001): 115-9
Garcia MJ, Dominguez-Gil A, Tabernero JM, Tomero JA "Pharmacokinetics of cefoxitin in patients with normal or impaired renal function." Eur J Clin Pharmacol 16 (1979): 119-24
Czerwinski AW, Pederson JA, Barry JP "Cefazolin plasma concentrations and urinary excretion in patients with renal impairment." J Clin Pharmacol 14 (1974): 560-6
Hardin TC, Butler SC, Ross S, Wakeford JH, Jorgensen JH "Comparison of ampicillin-sulbactam and ticarcillin-clavulanic acid in patients with chronic renal failure - effects of differential pharmacokinetics on serum bactericidal activity." Pharmacotherapy 14 (1994): 147-52
Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978): s88-97
Oe PL, Simonian S, Verhoef J "Pharmacokinetics of the new penicillins." Chemotherapy 19 (1973): 279-88
Benner EJ "Renal damage associated with prolonged administration of ampicillin, cephaloridine, and cephalothin." Antimicrob Agents Chemother 9 (1969): 417-20
Ortiz A, Martin-Llonch N, Garron MP, et al "Cefazolin-induced encephalopathy in uremic patients." Rev Infect Dis 13 (1991): 772-3
Ings RM, Reeves DS, White LP, et al "The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination." J Pharmacokinet Biopharm 13 (1985): 121-42
Hansen MM, Kaaber K "Nephrotoxicity in combined cephalothin and gentamicin therapy." Acta Med Scand 201 (1977): 463-7
Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971): 41-6
Mellin H-E, Welling PG, Madsen PO "Pharmacokinetics of cefamandole in patients with normal and impaired renal function." Antimicrob Agents Chemother 11 (1977): 262-6
Jusko WJ, Lewis GP, Schmitt GW "Ampicillin and hetacillin pharmacokinetics in normal and anephric subjects." Clin Pharmacol Ther 14 (1972): 90-9
Foord RD "Cephaloridine, cephalothin and the kidney." J Antimicrob Chemother 1 (1975): 119-33
al Shohaib S, Satti MS, Abunijem Z "Acute interstitial nephritis due to cefotaxime." Nephron 73 (1996): 725
"Product Information. Ticar (ticarcillin)." SmithKline Beecham, Philadelphia, PA.
Barriere SL, Gambertoglio JG, Alexander DR, et al "Pharmacokinetic disposition of cefonicid in patients with renal failure and receiving hemodialysis." Rev Infect Dis 6 (1984): s809-15
Smyth RD, Pfeffer M, Glick A, et al "Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin." Antimicrob Agents Chemother 16 (1979): 615-21
"Product Information. Claforan (cefotaxime)." Hoechst Marion-Roussel Inc, Kansas City, MO.
Craig CP, Rifkin SI "Pharmacokinetics and hemodialyzability of cefazolin in uremic patients." Clin Pharmacol Ther 19 (1976): 825-9
Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970): 57-9
Barrons RW, Murray KM, Richey RM "Populations at risk for penicillin-induced seizures." Ann Pharmacother 26 (1992): 26-9
Wu MJ, Narsette TA, Hussey JL, Weinstein AB, Wen SF "Cephalothin neurotoxicity in renal failure." Ann Intern Med 89 (1978): 429
New PS, Wells CE "Cerebral toxicity associated with massive intravenous penicillin therapy." Neurology 15 (1965): 1053-8
"Product Information. Cefadyl (cephapirin)." Apothecon Inc, Plainsboro, NJ.
Thompson MI, Russo ME, Matsen JM, Atkin-Thor E "Piperacillin pharmacokinetics in subjects with chronic renal failure." Antimicrob Agents Chemother 19 (1981): 450-3
Matzke GR, Abraham PA, Halstenson CE, Keane WF "Cefotaxime and desacetylcefotaxime kinetics in renal impairment." Clin Pharmacol Ther 38 (1985): 31-6
"Product Information. Pipracil (piperacillin)." Lederle Laboratories, Wayne, NJ.
"Product Information. Tazicef (ceftazidime)." SmithKline Beecham, Philadelphia, PA.
Engle JE, Drago J, Carlin B, Schoolwerth AC "Letter: Reversible acute renal failure after cephalothin." Ann Intern Med 83 (1975): 232-3
Blair AD, Maxwell BM, Forland SC, et al "Cefonicid kinetics in subjects with normal and impaired renal function." Clin Pharmacol Ther 35 (1984): 798-803
Ohkawa M, Okasho A, Motoi I, et al "Elimination kinetics of cefotaxime and desacetylcefotaxime in patients with renal insufficiency and during hemodialysis." Chemotherapy 29 (1983): 4-12
Doluisio JT "Clinical pharmacokinetics of cefotaxime in patients with normal and reduced renal function." Rev Infect Dis 4 Suppl (1982): s333-45
"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome, Research Triangle Park, NC.
Ohkawa M, Hirano S, Tokunaga S, et al "Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function." Antimicrob Agents Chemother 23 (1983): 31-5
Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Halstenson CE, Opsahl JA, Pittman KA "Disposition of the cephalosporin cefepime in normal and renally impaired subjects." Drug Metab Dispos 19 (1991): 68-73
Kowalsky SF, Echols RM, Venezia AR, Andrews EA "Pharmacokinetics of ceftizoxime in subjects with various degrees of renal function." Antimicrob Agents Chemother 24 (1983): 151-5
Bulger RJ, Lindholm DD, Murray JS, Kirby WM "Effects of uremia on methicillin and oxacillin blood levels." JAMA 187 (1964): 319-22
Jackson GD, Berkovic SF "Ceftazidime encephalopathy: absence status and toxic hallucinations." J Neurol Neurosurg Psychiatry 55 (1992): 333-4
Douglas MA, Quandt CM, Stanley DA "Ceftazidime-induced encephalopathy in a patient with renal impairment." Arch Neurol 45 (1988): 936-7
Simpson IJ "Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine." N Z Med J 74 (1971): 312-5
Nilsson-Ehle I, Nilsson-Ehle P "Pharmacokinetics of cephalothin: accumulation of its deacetylated metabolite in uremic patients." J Infect Dis 139 (1979): 712-6
Ings RM, Fillastre J-P, Godin M, et al "The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function." Rev Infect Dis 4 (1982): s379-91
Trollfors B, Ahlmen J, Alestig K "Renal function during cefoperazone treatment." J Antimicrob Chemother 9 (1982): 485-7
Csanyi P, Rado JP, Hormay M "Acute renal failure due to cephamandole." Br Med J 296 (1988): 455
Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972): 201-4
Leroy J, Leguy F, Borsa F, et al "Pharmacokinetics of ceftazidime in normal and uremic subjects." Antimicrob Agents Chemother 25 (1984): 638-42
Chow M, Quintiliani R, Cunha BA, et al "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979): 185-94
Parry MF, Neu HC "Pharmacokinetics of ticarcillin in patients with abnormal renal function." J Infect Dis 133 (1976): 46-9
Mihindu JC, Scheld WM, Bolton ND, Spyker DA, Swabb EA, Bolton K "Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction." Antimicrob Agents Chemother 24 (1983): 252-61
Brogard JM, Pinget M, Brandt C, Lavillaureix J "Pharmacokinetics of cefazolin in patients with renal failure: special reference to hemodialysis." J Clin Pharmacol 17 (1977): 225-30
Walstad RA, Dahl K, Hellum KB, et al "The pharmacokinetics of ceftazidime in patients with impaired renal function and concurrent frusemide therapy." Eur J Clin Pharmacol 35 (1988): 273-9
Czerwinski AW, Pederson JA "Pharmacokinetics of cefamandole in patients with renal impairment." Antimicrob Agents Chemother 15 (1979): 161-4
Welling PG, Craig WA, Amidon GL, Kunin CM "Pharmacokinetics of cefazolin in normal and uremic subjects." Clin Pharmacol Ther 15 (1973): 344-53
Hillsley RE, Massey EW "Truncal asterixis associated with ceftazidime, a third-generation cephalosporin." Neurology 41 (1991): 2008
Ackerman BH, Ross J, Tofte RW, Rotschafer JC "Effect of decreased renal function on the pharmacokinetics of ceftazidime." Antimicrob Agents Chemother 25 (1984): 785-6
Mackie K, Pavlin EG "Recurrent paralysis following piperacillin administration." Anesthesiology 72 (1990): 561-3
"Product Information. Monocid (cefonicid)." SmithKline Beecham, Philadelphia, PA.
Slaker RA, Danielson B "Neurotoxicity associated with ceftazidime therapy in geriatric patients with renal dysfunction." Pharmacotherapy 11 (1991): 351-2
Reitberg DP, Marble DA, Schultz RW, Whall TJ, Schentag JJ "Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis." Antimicrob Agents Chemother 32 (1988): 503-9
Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Guay DR, Pittman KA "Pharmacokinetics of cefepime in subjects with renal insufficiency." Clin Pharmacol Ther 48 (1990): 268-76
Toll LL, Lee M, Sharifi R "Cefoxitin-induced interstitial nephritis." South Med J 80 (1987): 274-5
Plaut ME, O'Connell CJ, Pabico RC, Davidson D "Penicillin handling in normal and azotemic patients." J Lab Clin Med 74 (1969): 12-8
Bryan CS, Stone WJ ""Comparably massive" penicillin G therapy in renal failure." Ann Intern Med 82 (1975): 189-95
Aronoff GR, Sloan RS, Stanish RA, Fineberg NS "Mezlocillin dose dependent elimination kinetics in renal impairment." Eur J Clin Pharmacol 21 (1982): 505-9
Barrientos A, Bello I, Gutierrez-Millet V "Letter; Renal failure and cephalothin." Ann Intern Med 84 (1976): 612
Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978): s88-99
Reddy J, Bailey RR "Cefoxitin-associated renal failure." N Z Med J 93 (1981): 337-9
Konishi K, Suzuki H, Hayashi M, Saruta T "Pharmacokinetics of cefuroxime axetil in patients with normal and impaired renal function." J Antimicrob Chemother 31 (1993): 413-20
"Product Information. Pfizerpen (penicillin)." Roerig Division, New York, NY.
Al-Zahawi MF, Sprott MS, Hendrick DJ "Hallucinations in association with ceftazidime." Br Med J 297 (1988): 858
Kabins SA, Cohen S "Cephalothin serum levels in the azotemic patient." Antimicrob Agents Chemother 10 (1964): 207-14
Arvidsson A, Borga O, Alvan G "Renal excretion of cephapirin and cephaloridine: evidence for saturable tubular reabsorption." Clin Pharmacol Ther 25 (1979): 870-6
"Product Information. Keflin (cephalothin)." Lilly, Eli and Company, Indianapolis, IN.
Brogard JM, Comte F, Spach MO, Lavillaureix J "Pharmacokinetics of mezlocillin in patients with kidney impairment: special reference to hemodialysis and dosage adjustments in relation to renal function." Chemotherapy 28 (1982): 318-26
Bundtzen RW, Toothaker RD, Nielson OS, et al "Pharmacokinetics of cefuroxime in normal and impaired renal function: comparison of high-pressure liquid chromatography and microbiological assays." Antimicrob Agents Chemother 19 (1981): 443-9
Hodgman T, Dasta JF, Armstrong DK, Visconti JA, Reilley TE "Ampicillin-associated seizures." South Med J 77 (1984): 1323-5
"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals, Wilmington, DE.
Giron JA, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of piperacillin in patients with moderate renal failure and in patients undergoing hemodialysis." Antimicrob Agents Chemother 19 (1981): 279-83
Bergan T, Brodwall EK, Orjavik O "Pharmacokinetics of cefazolin in patients with normal and impaired renal function." J Antimicrob Chemother 3 (1977): 435-43
Mangione A, Boudinot FD, Schultz RM, Jusko WJ "Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment." Antimicrob Agents Chemother 21 (1982): 428-35
Humbert G, Fillastre JP, Leroy A, Godin M, Van Winzum C "Pharmacokinetics of cefoxitin in normal subjects and in patients with renal insufficiency." Rev Infect Dis 1 (1979): 118-26
Goddard JK, Janning SW, Gass JS, Wilson RF "Cefuroxime-induced acute renal failure." Pharmacotherapy 14 (1994): 488-91
Alshohaib S, Satti MS, Abunijem Z "Acute interstitial nephritis due to cefotaxime." Nephron 73 (1996): 725
Czerwinski AW, Pederson JA "The pharmacology of cefamandole in patients with reduced renal function." Scand J Infect Dis 25 (1980): 45-8
Pasmino P "Acute renal failure, skin rash, and eosinophilia associated with aztreonam." Am J Nephrol 8 (1988): 68-70
Nielsen OS, Toothaker RD, Bundtzen RW, et al "Cefotaxime pharmacokinetics following a single intravenous dose to patients with varying renal function." Infection 8 (1980): s305-9
Welling PG, Craig WA, Bundtzen RW, et al "Pharmacokinetics of piperacillin in subjects with various degrees of renal function." Antimicrob Agents Chemother 23 (1983): 881-7
"Product Information. Ancef (cefazolin)." SmithKline Beecham, Philadelphia, PA.
Trang JM, Monson TP, Ackerman BH, et al "Effect of age and renal function on cefonicid pharmacokinetics." Antimicrob Agents Chemother 33 (1989): 142-6
Bergan T, Orjavik O, Brodwall EK "Pharmacokinetics of cefapirin in patients with normal and impaired renal functions." Arzneimittelforschung 31 (1981): 1773-6
"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn, Kalamazoo, MI.
Pickering MJ, Spooner GR, Quesada A, de Cade JR "Declining renal function associated with administration of cephalothin." South Med J 63 (1970): 426-8
Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979): 429-51
Wright N, Wise R, Hegarty T "Cefotetan elimination in patients with varying degrees of renal dysfunction." J Antimicrob Chemother 1 (1983): 213-6
Pascual J, Liano F, Ortuno J "Cefotaxime-induced encephalopathy in an uremic patient." Nephron 54 (1990): 92
Appel GB, Neu HC, Parry MF, et al "Pharmacokinetics of cefamandole in the presence of renal failure and in patients undergoing hemodialysis." Antimicrob Agents Chemother 10 (1976): 623-5
Fanning WL, Gump D, Jick H "Gentamicin- and cephalothin-associated rises in blood urea nitrogen." Antimicrob Agents Chemother 10 (1976): 80-2
Palla R, Panichi V, Bionda A, et al "Acute renal failure after mezlocilline." Clin Nephrol 25 (1986): 315-6
Jungbluth GL, Cooper DL, Doyle GD, Chudzik GM, Jusko WJ "Pharmacokinetics of ticarcillin and clavulanic acid (timentin) in relation to renal function." Antimicrob Agents Chemother 30 (1986): 896-900
"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Johnson CA, Halstenson CE, Kelloway JS, et al "Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease." Clin Pharmacol Ther 51 (1992): 32-41
Nguyen VD, Nagelberg H, Agarwal BN "Acute interstitial nephritis associated with cefotetan therapy." Am J Kidney Dis 16 (1990): 259-61
van Dalen R, Vree TB, Baars AM, Termond E "Dosage adjustment for ceftazidime in patients with impaired renal function." Eur J Clin Pharmacol 30 (1986): 597-605
Bloomer HA, Barton LJ, Maddock RK "Penicillin-induced encephalopathy in uremic patients." JAMA 200 (1967): 121-3
Phelps RT, Conte JE "Multiple-dose pharmacokinetics of cefonicid in patients with impaired renal function." Antimicrob Agents Chemother 29 (1986): 913-7
Ohkawa M, Okasho A, Sugata T, Kuroda K "Elimination kinetics of ceftizoxime in humans with and without renal insufficiency." Antimicrob Agents Chemother 22 (1982): 308-11
"Product Information. Cefizox (ceftizoxime)." Fujisawa, Deerfield, IL.
Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985): s145-50